Conclusion
At the moment, there is not enough research to scientifically
substantiate one or another approach to the treatment of patients with
hemoblastosis and coronavirus infection. In our experience, we evaluated
the effect of complex therapy in patients with hematopoietic
malignancies and depression of hematopoiesis with COVID-19, without
interrupting chemotherapy. The proposed protocol will presumably reduce
the risks of recurrence and refractoriness of the underlying disease.
Because of the above, the tactics of managing patients with
hematological malignancies in the context of COVID-19 requires further
study, which we plan to do in the future.